F. Czerwiec

Publications63
h-index26
Citations4,695
Highly Influential Citations207
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • V. Torres
  • 438 Publications, 26,530 Citations
  • A. Chapman
  • 216 Publications, 8,015 Citations
  • R. Gansevoort
  • 538 Publications, 29,710 Citations
  • J. Grantham
  • 284 Publications, 17,053 Citations
  • Publications
  • Influence
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
BACKGROUND The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin… Expand
  • 902
  • 48
  • PDF
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
BACKGROUND Hyponatremia (serum sodium concentration, <135 mmol per liter) is a predictor of death among patients with chronic heart failure and cirrhosis. At present, therapy for acute and chronic… Expand
  • 1,010
  • 39
Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial
Background—In this study, we evaluated the effects of tolvaptan (OPC-41061), a novel, oral, nonpeptide vasopressin V2-receptor antagonist in patients with chronic heart failure (CHF). Methods and… Expand
  • 400
  • 15
Oral tolvaptan is safe and effective in chronic hyponatremia.
Vasopressin antagonists increase the serum sodium concentration in patients who have euvolemia and hypervolemia with hyponatremia in the short term (</=30 days), but their safety and efficacy with… Expand
  • 278
  • 13
  • PDF
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Tolvaptan and related V(2)-specific vasopressin receptor antagonists have been shown to delay disease progression in animal models of polycystic kidney disease. Slight elevations in serum creatinine,… Expand
  • 96
  • 11
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.
OBJECTIVE Tolvaptan, an oral antagonist of the vasopressin V(2) receptor, has been found to improve hyponatremia in patients with mixed etiologies. This study analyzed a subgroup of patients with the… Expand
  • 138
  • 10
  • PDF
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
IntroductionSubjects with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan experienced aminotransferase elevations more frequently than those on placebo in the TEMPO 3:4… Expand
  • 106
  • 9
  • PDF
Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease
Background In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2‐receptor… Expand
  • 176
  • 8
  • PDF
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
BACKGROUND & AIMS Tolvaptan is a vasopressin V2-receptor antagonist that improves serum sodium concentration by increasing renal solute-free water excretion. Specific data on the safety and efficacy… Expand
  • 108
  • 8
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
BACKGROUND AND OBJECTIVES Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease… Expand
  • 137
  • 7
  • PDF